AVITA Therapeutics Recorded US$14.32 Million Sales in FY20

AVITA Therapeutics Inc (ASX:AVH) revealed preliminary Q4 and FY20 results, together with a company update.

  • In the fourth quarter, total global net revenue for the fourth quarter stood at US$3.88 million and total consolidated sales for FY20 (year ended 30 June 2020) were reported to be US$14.32 million.
  • S. RECELL® System sales in Q4 and FY20 reported to be US$3.79 million and US$13.79 million, respectively.
  • At the end of the fourth quarter, AVITA had cash and cash equivalents of nearly US$73.84 million.

AVH quoted at A$8.140 down by 4.46% at AEST 12:31 PM.

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK